subject area of

• A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma  Academic Article
• A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design  Academic Article
• A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen  Academic Article
• A Prospective Study of Incident Nonmelanoma Skin Cancer in Heart Transplant Recipients  Academic Article
• A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35  Academic Article
• A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma  Academic Article
• A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: Synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation  Academic Article
• A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme  Academic Article
• ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling  Academic Article
• Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor  Academic Article
• Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells  Academic Article
• Altered expression and splicing of ESRP1 in malignant melanoma correlates with epithelial- mesenchymal status and Tumor-Associated immune cytolytic activity  Academic Article
• An HLA-A2 polyepitope vaccine for melanoma immunotherapy  Academic Article
• An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma  Academic Article
• Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non–small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors  Academic Article
• B Cells and Antibody Production in Melanoma  Academic Article
• BRAF V600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells  Academic Article
• BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage  Academic Article
• Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deployment  Academic Article
• Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients  Academic Article
• Brief report: Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile  Academic Article
• Cancer evolution during immunotherapy  Academic Article
• Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate  Academic Article
• Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells  Academic Article
• Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces  Academic Article
• Cardiac metastases from malignant melanoma  Academic Article
• Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma  Academic Article
• Characterising the phenotypic evolution of circulating tumour cells during treatment  Academic Article
• Characteristics of pyrexia in BRAF V600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial  Academic Article
• Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination  Academic Article
• Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial  Academic Article
• Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma  Academic Article
• Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma  Academic Article
• Clinical promise of tumour immunology  Academic Article
• Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT  Academic Article
• Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma  Academic Article
• Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies  Academic Article
• Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAF V600 -mutant melanoma experiencing progression with single-agent BRAF inhibitor  Academic Article
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations  Academic Article
• Combining MHC tetramer and intracellular cytokine staining for CD8+ T cells to reveal antigenic epitopes naturally presented on tumor cells  Academic Article
• Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents  Academic Article
• Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens  Academic Article
• Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance  Academic Article
• Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens  Academic Article
• Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade  Academic Article
• Distinct Clinical and Pathological Features Are Associated with the BRAFT1799A(V600E) Mutation in Primary Melanoma  Academic Article
• Early Growth Response Gene 1 (EGR1) Regulates Heparanase Gene Transcription in Tumor Cells  Academic Article
• Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy  Academic Article
• Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases  Academic Article
• Evolving role of tumor antigens for future melanoma therapies  Academic Article
• Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma  Academic Article
• FOXP3 is not mutated in human melanoma  Academic Article
• FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.  Academic Article
• Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients’ sera using short overlapping peptides and full-length recombinant protein  Academic Article
• First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors  Academic Article
• Fourier transform infrared imaging as a method for detection of HLA class I expression in melanoma without the use of antibody  Academic Article
• Frequent MAGE Mutations in Human Melanoma  Academic Article
• Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli  Academic Article
• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients  Academic Article
• Heat Shock Protein Levels Are Not Elevated in Heat-Resistant B16 Melanoma Cells  Academic Article
• Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM  Academic Article
• Identifying and targeting determinants of melanoma cellular invasion  Academic Article
• Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment  Academic Article
• Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™  Academic Article
• Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1  Academic Article
• Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma  Academic Article
• Immunotherapy of advanced or metastatic melanoma  Academic Article
• Immunotherapy of melanoma: Targeting defined antigens  Academic Article
• Immunotherapy resistance: the answers lie ahead – not in front – of us  Academic Article
• Impact of 2-Deoxy-2[F-18]Fluoro-d-Glucose Positron Emission Tomography on the Management of Patients with Advanced Melanoma  Academic Article
• Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ1  Academic Article
• Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors  Academic Article
• Iterative sorting reveals CD133+and CD133-melanoma cells as phenotypically distinct populations  Academic Article
• Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma  Academic Article
• Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines  Academic Article
• Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX (TM) vaccine in patients with advanced melanoma  Academic Article
• MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma  Academic Article
• Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4  Academic Article
• Melanoma vaccines: developments over the past 10 years  Academic Article
• Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations  Academic Article
• Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure  Academic Article
• Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro  Academic Article
• NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus  Academic Article
• Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma  Academic Article
• Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial  Academic Article
• Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma  Academic Article
• Novel Imaging Techniques in Melanoma  Academic Article
• Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy  Academic Article
• Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists  Academic Article
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma  Academic Article
• Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib  Academic Article
• PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation  Academic Article
• Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma  Academic Article
• Periarticular FDG uptake on PET/CT in malignant melanoma-metastatic or misleading?  Case Study
• Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma  Academic Article
• Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma  Academic Article
• Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion  Academic Article
• Primary malignant melanoma of the urinary bladder and ureter  Academic Article
• Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies  Academic Article
• Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma  Academic Article
• Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma  Academic Article
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans  Academic Article
• Regioselective acylation of 3-O-angeloylingenol by Candida antarctica Lipase B  Academic Article
• Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma  Academic Article
• Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’  Letter
• Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma  Academic Article
• Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP  Academic Article
• Role of nuclear medicine in the management of cutaneous malignant melanoma  Academic Article
• SCL gene in human tumors  Academic Article
• Season of diagnosis has no effect on survival from malignant melanoma  Academic Article
• Sentinel node biopsy for melanoma: The medical oncology perspective  Letter
• Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells - Evidence of unique microRNA cargos  Academic Article
• Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial  Academic Article
• Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-GD3 ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts  Academic Article
• Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects  Academic Article
• Standard of care in immunotherapy trials: challenges and considerations  Academic Article
• Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029) : an open-label, phase 1b trial  Academic Article
• Synergism between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cells  Academic Article
• Systems analysis identifies miR-29b regulation of invasiveness in melanoma  Academic Article
• Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure  Academic Article
• The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel  Academic Article
• The Regulatory T Cell-Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells  Academic Article
• The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.  Academic Article
• The role of BRAF mutations in primary melanoma growth rate and survival  Academic Article
• The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells  Academic Article
• The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma  Academic Article
• The use of dendritic cells in cancer therapy  Academic Article
• Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma  Academic Article
• Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells  Academic Article
• Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage  Academic Article
• Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery  Academic Article
• Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma  Editorial Article
• Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes  Academic Article
• Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.  Academic Article
• Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma  Academic Article
• Whole-genome landscapes of major melanoma subtypes  Academic Article